secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-08-03T20:02:02+00:00
Accession:  0001664710-26-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics Q2 2026 net loss $28.7M; initiates Phase 2 DMD trial for rinvatercept
--------------------------------------------------------------------------------

- Net loss of $28.7M in Q2 2026 vs $30.7M in Q2 2025; R&D expenses down to $22.3M from $43.5M.
- Cash and cash equivalents $257.6M as of June 30, 2026; expected to fund operations into first half 2028.
- Initiated Phase 2 clinical trial of rinvatercept in Duchenne muscular dystrophy; initial data expected first half 2027.
- General and administrative expenses decreased to $8.6M from $14.5M due to restructuring and lower professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/0001664710-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/kros-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer